Universal Beteiligungs und Servicegesellschaft mbH Invests $254,000 in Denali Therapeutics Inc. (NASDAQ:DNLI)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH acquired 18,699 shares of Denali Therapeutics Inc. (NASDAQ:DNLI), valued at approximately $254,000, in the first quarter.
• CEO Ryan J. Watts sold 495,282 shares of Denali stock for a total of about $7.4 million, reducing his ownership by 66.18%.
• Analysts have mixed ratings for Denali Therapeutics, with a consensus "Buy" rating and a target price of $33.85, despite recent price reductions from several research firms.

Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 18,699 shares of the company's stock, valued at approximately $254,000.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Raymond James Financial Inc. bought a new position in Denali Therapeutics during the fourth quarter valued at about $533,000. Norges Bank acquired a new stake in Denali Therapeutics during the fourth quarter worth about $21,717,000. Pictet Asset Management Holding SA boosted its holdings in Denali Therapeutics by 17.0% during the fourth quarter. Pictet Asset Management Holding SA now owns 19,356 shares of the company's stock valued at $394,000 after purchasing an additional 2,806 shares in the last quarter. Trexquant Investment LP boosted its holdings in Denali Therapeutics by 147.2% during the fourth quarter. Trexquant Investment LP now owns 60,656 shares of the company's stock valued at $1,236,000 after purchasing an additional 36,122 shares in the last quarter. Finally, Envestnet Asset Management Inc. boosted its holdings in shares of Denali Therapeutics by 34.5% in the 4th quarter. Envestnet Asset Management Inc. now owns 37,622 shares of the company's stock worth $767,000 after acquiring an additional 9,643 shares in the last quarter. Institutional investors and hedge funds own 92.92% of the company's stock.

Insider Activity at Denali Therapeutics

In related news, CEO Ryan J. Watts sold 495,282 shares of the stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $15.00, for a total transaction of $7,429,230.00. Following the transaction, the chief executive officer owned 253,071 shares of the company's stock, valued at approximately $3,796,065. This trade represents a 66.18% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 12.50% of the company's stock.

Denali Therapeutics Stock Performance

Denali Therapeutics stock traded down $0.15 during midday trading on Tuesday, reaching $14.29. 2,087,799 shares of the stock were exchanged, compared to its average volume of 1,516,625. The company's fifty day moving average is $14.25 and its 200-day moving average is $15.79. The firm has a market cap of $2.08 billion, a PE ratio of -5.35 and a beta of 1.36. Denali Therapeutics Inc. has a 52 week low of $10.57 and a 52 week high of $33.33.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.78) EPS for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.07). During the same period in the previous year, the company earned ($0.68) EPS. On average, sell-side analysts anticipate that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Wedbush reduced their price objective on Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. TD Cowen raised shares of Denali Therapeutics to a "strong-buy" rating in a report on Monday, July 28th. Robert W. Baird decreased their price objective on shares of Denali Therapeutics from $30.00 to $29.00 and set an "outperform" rating on the stock in a research note on Thursday, May 8th. William Blair upgraded shares of Denali Therapeutics to a "strong-buy" rating in a report on Thursday, April 24th. Finally, Cantor Fitzgerald raised shares of Denali Therapeutics from a "neutral" rating to an "overweight" rating in a research note on Thursday, April 10th. One equities research analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $33.85.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.